ELI LILLY & Co (New York Stock Exchange:LLY)
| Market Cap | 1.06T+49.8% |
| Revenue (ttm) | 79.67B+49.6% |
| Net Income | 26.71B+93.5% |
| EPS | 29.80+94.8% |
| Shares Out | 941.74M |
| PE Ratio | 37.66 |
| Forward PE | 24.10 |
| Dividend | $6.69(0.60%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 2,013,187 |
| Open | 1126.54 |
| Previous Close | 1123.91 |
| Day's Range | 1119.01 - 1138.70 |
| 52-Week Range | 712.05 - 1292.65 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 1345.40(+19.68%) |
| Earnings Date | Oct 29, 2026 |
About LLY
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LLY stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of LLY by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Michael RulliHouse / R | Sale$1.00K – $15.00K | Jul 1, 2026 |
| Michael A. RulliHouse / R | Sale$1.00K – $15.00K | Jul 1, 2026 |
| David J. TaylorHouse / R | Purchase$1.00K – $15.00K | Feb 25, 2026 |
| David J. TaylorHouse / R | Sale$1.00K – $15.00K | Feb 8, 2026 |
| David J. TaylorHouse / R | Sale$1.00K – $15.00K | Jan 15, 2026 |
| Michael RulliHouse / R | Purchase$1.00K – $15.00K | Jan 2, 2026 |
| Michael A. RulliHouse / R | Purchase$1.00K – $15.00K | Jan 2, 2026 |
| David J. TaylorHouse / R | Sale$1.00K – $15.00K | Dec 9, 2025 |
Recently reported changes in LLY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LLY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LLY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LLY Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New LLY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LLY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LLY
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $31.01B |
| VOOVanguard S&P 500 ETF | $23.86B |
| IVViShares Core S&P 500 ETF | $12.00B |
| SPYState Street SPDR S&P 500 ETF | $10.91B |
| VUGVanguard Morningstar Growth ETF | $10.12B |
| XLVState Street Health Care Select Sector SPDR ETF | $6.56B |
Estimated from each fund’s disclosed top holdings × AUM
LLY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LLY’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score